09
Jun
2009
Posted in I - Series A, Q - 2Q09, R - WEST, X - Atrimer, X - Immunology, X - Oncology
Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $13M Series A bring the total round of financing to $38M. Participants include SR One, Merck Serono Ventures, 5AM Ventures, Apposite Capital and Versant Ventures.
12
Jan
2009